


## LpxH-IN-AZ1

<b>Cat. No.:</b>	HY-130836		
<b>CAS No.:</b>	901260-40-0		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>22</sub> F <sub>3</sub> N <sub>3</sub> O <sub>3</sub> S		
<b>Molecular Weight:</b>	453.48		
<b>Target:</b>	Bacterial		
<b>Pathway:</b>	Anti-infection		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 25 mg/mL (55.13 mM; ultrasonic and warming and heat to 60°C)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.2052 mL	11.0258 mL	22.0517 mL
	5 mM	0.4410 mL	2.2052 mL	4.4103 mL
	10 mM	0.2205 mL	1.1026 mL	2.2052 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

LpxH-IN-AZ1, a sulfonyl piperazine compound, is a potent UDP-2,3-diacylglucosamine pyrophosphatase LpxH inhibitor. LpxH-IN-AZ1 is a potent inhibitor of *Klebsiella pneumoniae* LpxH with IC<sub>50</sub> of 0.36 μM<sup>[1]</sup>.

#### In Vitro

LpxH-IN-AZ1 displays IC<sub>50</sub> values of 0.36 μM against *K. pneumoniae* LpxH and 0.14 μM against *E. coli* LpxH, respectively<sup>[1]</sup>. LpxH-IN-AZ1 (1 μM) inhibits 75% of the activity of *K. pneumoniae* LpxH and 83% of the activity of *E. coli* LpxH in the presence of 100 μM UDPDAGn<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Cho J, et al. Structural basis of the UDP-diacylglucosamine pyrophosphohydrolase LpxH inhibition by sulfonyl piperazine antibiotics. Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4109-4116.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA